Disclosures for "Neuroprotective Potential of Glucagon-Like Peptide-1 Receptor Agonists in Multiple Sclerosis: A Retrospective Cohort Study Using TriNetX"
-
Ms. Irfan has nothing to disclose.
-
Ms. Lakin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Ms. Lakin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Ms. Lakin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Ms. Lakin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Allergan. The institution of Ms. Lakin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Ms. Lakin has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono. The institution of Ms. Lakin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for TG Therapeutics. The institution of Ms. Lakin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Ms. Lakin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen.
-
The institution of Dr. Khayat-Khoei has received research support from The National MS Society of America, for Fellowship Award.